Menu Healthgrades for Professionals Account Sign In
Healthgrades for Professionals

KYNMOBI apomorphine hydrochloride

Get an overview of KYNMOBI (apomorphine hydrochloride film, soluble), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why it’s used. The medication in KYNMOBI can be sold under different names.

Refer to the “Also Known As” section to reference different products that include the same medication as KYNMOBI.

Drug Basics

Brand Name: KYNMOBI

Generic Name: APOMORPHINE HYDROCHLORIDE

Drug Type: HUMAN PRESCRIPTION DRUG

Route: SUBLINGUAL

Dosage Form: FILM, SOLUBLE

Packager: Sunovion Pharmaceuticals Inc.

Data Current As Of: 2021-04-26

Indications & Usage

KYNMOBI is indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson's disease (PD).

KYNMOBI is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of “off” episodes in patients with Parkinson's disease (1)

Drug Abuse & Dependence

controlled substance

KYNMOBI contains apomorphine, which is not a controlled substance.

abuse

In premarketing clinical experience, KYNMOBI did not reveal any tendency for a withdrawal syndrome or any drug-seeking behavior. However, there are rare postmarketing reports of abuse of medications containing apomorphine. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. In general, these reports for apomorphine consist of patients taking increasing doses of medication in order to achieve a euphoric state.

Patient Counseling Information

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Administration of KYNMOBI

Advise patients that KYNMOBI is for sublingual use only [see Dosage and Administration (2.1)].

KYNMOBI must be administered whole. Advise patients not to cut, chew, or swallow KYNMOBI.

Nausea and Vomiting

Advise patients that KYNMOBI may cause nausea and vomiting when it is administered at recommended doses. Treatment with an antiemetic (e.g., trimethobenzamide) may be used, as needed, if nausea or vomiting occurs. Inform patients that they should discuss with their healthcare provider when the antiemetic can be discontinued [see Warnings and Precautions (5.1)].

Falling Asleep During Activities of Daily Living and Somnolence

Alert patients to the potential sedating effects of KYNMOBI, including somnolence and falling asleep while engaged in activities of daily living. Instruct patients not to drive a car or engage in other potentially dangerous activities until they have gained sufficient experience with KYNMOBI to gauge whether or not it affects their mental and/or motor performance adversely. Advise patients that if increased somnolence or episodes of falling asleep during activities of daily living (e.g., watching television, passenger in a car, etc.) occur, they should not drive or participate in potentially dangerous activities until they have discussed this with their healthcare provider. Because of possible additive effects of alcohol use, advise patients to limit their alcohol intake [see Warnings and Precautions (5.2)].

Hypersensitivity / Allergic Reactions

Advise patients that hypersensitivity/allergic reaction (e.g., swelling of the lips, tongue and mouth, flushing, and, infrequently, urticaria and throat tightness) may occur because of apomorphine, sodium metabisulfite, or any KYNMOBI excipients. Inform patients with a sulfite sensitivity that KYNMOBI contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes [see Warnings and Precautions (5.3)]. Advise patients who experience any hypersensitivity/allergic reaction to KYNMOBI that they should avoid taking KYNMOBI again [see Contraindications (4)].

Hypotension/Orthostatic Hypotension

Advise patients that they may develop postural (orthostatic) hypotension with or without symptoms, such as dizziness, nausea, syncope, and sweating. Instruct patients to rise slowly after sitting or lying down after taking KYNMOBI. Instruct patients to limit their alcohol intake because it may potentiate the hypotensive effect of KYNMOBI. Instruct patients to lie down before and after taking sublingual nitroglycerin because it may potentiate the hypotensive effect of KYNMOBI [see Warnings and Precautions (5.4)].

Oral Mucosal Irritation

Inform patients that KYNMOBI may result in oral mucosal adverse reactions such as irritation, erythema, lip swelling, mouth ulceration, dry mouth, stomatitis, glossodynia, oropharyngeal pain, swollen tongue, ageusia, oral pain, lip ulceration, oral disorder and hypoaesthesia oral [see Warnings and Precautions (5.5) and Adverse Reactions (6.1)].

Falls

Alert patients that they may have increased risk for falling when using KYNMOBI [see Warnings and Precautions (5.6)].

Hallucinations and/or Psychotic-Like Behavior

Inform patients that KYNMOBI may cause hallucinations or other manifestations of psychotic-like behavior. Advise patients to inform their healthcare provider if they have a major psychotic disorder or are taking any treatments for psychosis [see Warnings and Precautions (5.7)].

Impulse Control / Compulsive Behaviors

Patients and their caregivers should be alerted to the possibility that they may experience intense urges to spend money uncontrollably, intense urges to gamble, increased sexual urges, binge eating and/or other intense urges and the inability to control these urges while taking KYNMOBI [see Warnings and Precautions (5.8)].

Withdrawal-Emergent Hyperpyrexia and Confusion

Advise patients to contact their healthcare provider if they wish to discontinue KYNMOBI or decrease the dose of KYNMOBI [see Warnings and Precautions (5.9)].

QTc Prolongation and Potential for Proarrhythmic Effects

Alert patients that KYNMOBI may cause QTc prolongation and might produce proarrhythmic effects that could cause torsades de pointes and sudden death. Palpitations and syncope may signal the occurrence of an episode of torsades de pointes [see Warnings and Precautions (5.10)].

Priapism

Advise patients that KYNMOBI may cause prolonged painful erections and that if this occurs that they should seek medical attention immediately [see Warnings and Precautions (5.12)].

kyn00 0007 03.jpg

Manufactured for:
Sunovion Pharmaceuticals Inc.
Marlborough, Massachusetts 01752 USA

KYNMOBI is a trademark of Sunovion Pharmaceuticals Inc.
SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co. Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co. Ltd.
©2020 Sunovion Pharmaceuticals Inc. All rights reserved.
For more information, go to www.KYNMOBI.com or call Sunovion Customer Service at 1-888-394-7377.

10413-01

This Patient Information has been approved by the U.S. Food and Drug Administration Issued: 5/2020

Patient Information
KYNMOBI™ (kin-moe′-bee)
(apomorphine hydrochloride)
sublingual film
Read this Patient Information before you start taking KYNMOBI and each time you get a refill. There may be new information. This Patient Information does not take the place of talking to your healthcare provider about your medical condition or treatment.
What is KYNMOBI?
KYNMOBI is a prescription medicine used to treat short-term (acute), intermittent “off” episodes in people with Parkinson's disease (PD).
It is not known if KYNMOBI is safe and effective in children.

Do not take KYNMOBI if you are:

  • taking certain medicines to treat nausea called 5HT3 antagonists including ondansetron, granisetron, dolasetron, palonosetron, and alosetron. People taking ondansetron together with apomorphine, the active ingredient in KYNMOBI, have had very low blood pressure and lost consciousness or “blacked out.”
  • allergic to apomorphine hydrochloride or to any of the ingredients in KYNMOBI. See the end of the Patient Information leaflet for a complete list of ingredients in KYNMOBI.
    KYNMOBI also contains a sulfite called sodium metabisulfite. Sulfites can cause severe, life-threatening allergic reactions in some people. An allergy to sulfites is not the same as an allergy to sulfa. People with asthma are more likely to be allergic to sulfites.
    Call your healthcare provider or get emergency help right away if you get any of the following symptoms of a severe life-threatening allergic reaction:
  • hives
  • itching
  • rash
  • swelling of the lips, tongue, and mouth
  • redness of your face (flushing)
  • throat tightness
  • trouble breathing or swallowing
Before you start taking KYNMOBI, tell your healthcare provider about all of your medical conditions, including if you:
  • have difficulty staying awake during the daytime.
  • have dizziness.
  • have fainting spells.
  • have low blood pressure.
  • have asthma.
  • are allergic to any medicines containing sulfites
  • have liver problems.
  • have kidney problems.
  • have heart problems.
  • have had a stroke or other brain problems.
  • have a mental problem called a major psychotic disorder.
  • drink alcohol.
  • are pregnant or plan to become pregnant. It is not known if KYNMOBI will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if KYNMOBI passes into your breast milk. You and your healthcare provider should decide if you will take KYNMOBI or breastfeed.
  • Tell your healthcare provider about all the medicines you take, including prescription medicines and, over-the-counter medicines, vitamins, and herbal supplements.
KYNMOBI may affect the way other medicines work, and other medicines can affect how KYNMOBI works.
Taking KYNMOBI with other medicines may cause serious side effects.
  • If you take nitroglycerin under your tongue (sublingual) while using KYNMOBI, your blood pressure may decrease and cause dizziness. You should lie down before and after taking sublingual nitroglycerin.
Know the medicines you take. Keep a list of your medicines with you and show it to your healthcare provider and pharmacist when you get a new medicine.
How should I take KYNMOBI?
  • Read the step-by-step Instructions for Use that comes with your KYNMOBI prescription.
  • Take KYNMOBI exactly as your healthcare provider tells you to take it.
  • Your healthcare provider will tell you how much KYNMOBI to take and teach you the right way to take it.
  • Your healthcare provider may change your dose if needed.
  • Do not change your dose of KYNMOBI or take it more often than prescribed unless your healthcare provider has told you to.
  • Do not take more than 1 dose of KYNMOBI to treat a “OFF” episode.
  • Do not take another dose of KYNMOBI sooner than 2 hours after the last dose.
  • Do not take KYNMOBI more than 5 times a day.
  • Do not cut, chew or swallow KYNMOBI.
  • Your healthcare provider may prescribe another medicine for nausea called an antiemetic to take while you are taking KYNMOBI. Antiemetic medicines help to decrease the symptoms of nausea and vomiting that can happen when you take KYNMOBI.
What should I avoid while taking KYNMOBI?
  • Do not drink alcohol while you are taking KYNMOBI. It can increase your chance of developing serious side effects.
  • Do not take medicines that make you sleepy while you are using KYNMOBI.
  • Do not drive, operate machinery, or do other dangerous activities until you know how KYNMOBI affects you.
  • Do not change your body position too fast. Get up slowly from sitting or lying. KYNMOBI can lower your blood pressure and cause dizziness or fainting.
What are the possible side effects of KYNMOBI?
KYNMOBI can cause serious side effects, including:
  • nausea and vomiting. Nausea is a common side effect of KYNMOBI. Nausea and vomiting can happen with KYNMOBI. Your healthcare provider may prescribe a medicine called an antiemetic, such as trimethobenzamide, to help prevent nausea and vomiting. Some patients can stop taking trimethobenzamide after using KYNMOBI, when advised by your healthcare provider. Some patients may need to keep taking trimethobenzamide to help treat nausea and vomiting. Talk to your healthcare provider before you stop taking trimethobenzamide.
  • sleepiness or falling asleep during the day. Sleepiness is a serious and common side effect of KYNMOBI. Some people treated with KYNMOBI may get sleepy during the day or fall asleep without warning while doing everyday activities such as talking, eating, or driving a car.
  • allergic reactions. See the “ Do not take KYNMOBI if you are ” section.
  • dizziness. Dizziness is a serious, and common side effect of KYNMOBI. KYNMOBI may lower your blood pressure and cause dizziness. Dizziness can happen when KYNMOBI treatment is started or when the KYNMOBI dose is increased. Do not get up too fast from sitting or after lying down, especially if you have been sitting or lying down for a long period of time.
  • mouth (oral) irritation. Mouth (oral) irritation is a common side effect of KYNMOBI. You should call your healthcare provider if you develop any of these signs or symptoms:
  • redness
  • swelling
  • mouth sores (ulceration)
  • pain
  • dryness of the mouth, lips or tongue
  • pain with swallowing
These signs and symptoms may go away if KYNMOBI treatment is stopped.
  • falls. The changes that can happen with PD, and the effects of some PD medicines, can increase the risk of falling. KYNMOBI may also increase your risk of falling.
  • hallucinations or psychotic-like behavior. KYNMOBI may cause or make psychotic-like behavior worse including hallucinations (seeing or hearing things that are not real), confusion, excessive suspicion, aggressive behavior, agitation, delusional beliefs (believing things that are not real), and disorganized thinking.
  • strong (intense) urges. Some people with PD have reported new or strong uncontrollable urges to gamble, increased sexual urges, increased urges to spend money (compulsive shopping), and other intense urges, while taking PD medicines, including KYNMOBI. If you or your family members notice that you have strong urges, talk to your healthcare provider. The strong urges may go away if your KYNMOBI dose is lowered or stopped.
  • high fever and confusion. KYNMOBI may cause a problem that can happen in people who suddenly lower their dose, stop using, or change their dose of KYNMOBI. Symptoms include:
  • very high fever
  • stiff muscles
  • confusion
  • changes in breathing and heartbeat
Do not stop taking KYNMOBI or change your dose unless you are told to do so by your healthcare provider.
  • heart problems. If you have shortness of breath, fast heartbeat, chest pain, or feel like you are going to pass out (faint) while taking KYNMOBI, call your healthcare provider or get emergency help right away.
  • tissue changes (fibrotic complications). Some people have had changes in the tissues of their pelvis, lungs, and heart valves when taking medicines called nonergot derived dopamine agonists like KYNMOBI.
  • prolonged painful erections (priaprism). KYNMOBI may cause prolonged, painful erections in some people. If you have a prolonged and painful erection you should call your healthcare provider or go to the nearest hospital emergency room right away.
If you have any of these symptoms, stop taking KYNMOBI and call your healthcare provider right away before
taking another dose.
The most common side effects of KYNMOBI include:
  • nausea
  • sleepiness
  • dizziness
  • mouth swelling, pain, or sores
These are not all of the possible side effects of KYNMOBI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store KYNMOBI?
  • Store KYNMOBI at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep KYNMOBI in the foil pouch until you are ready to take it.
Keep KYNMOBI and all medicines out of the reach of children.
General information about the safe and effective use of KYNMOBI.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KYNMOBI for a condition for which it was not prescribed. Do not give KYNMOBI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about KYNMOBI that is written for health professionals.

What are the ingredients in KYNMOBI?
Active ingredient: apomorphine hydrochloride
Inactive ingredients: disodium EDTA, dihydrate, FD&C Blue #1, glycerol, glyceryl monostearate, hydroxyethyl cellulose, hypromellose, maltodextrin, (-)-menthol, pyridoxine hydrochloride, sodium hydroxide, sodium metabisulfite, sucralose, and white ink.

kyn00 0007 03.jpg


Manufactured for:
Sunovion Pharmaceuticals Inc.
Marlborough, Massachusetts 01752 USA

KYNMOBI is a trademark of Sunovion Pharmaceuticals Inc.
SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co. Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co. Ltd.
©2020 Sunovion Pharmaceuticals Inc. All rights reserved.
For more information, go to www.KYNMOBI.com or call Sunovion Customer Service at 1-888-394-7377.
10413-01

INSTRUCTIONS FOR USE
KYNMOBI TM (kin-moe′-bee)
(apomorphine hydrochloride)
Sublingual Film
Read this Instructions for Use before you start taking KYNMOBI and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.
Important
  • KYNMOBI is for sublingual (under your tongue) use only.
  • KYNMOBI must be taken whole. Do not cut, chew, or swallow KYNMOBI.
  • Do not take KYNMOBI until you talk with your healthcare provider about how to take it.
  • Check the expiration date printed on the foil pouch. Do not use KYNMOBI if the expiration date has passed.
  • Do not take more than 1 dose of KYNMOBI every 2 hours.
  • Do not take more than 5 doses of KYNMOBI each day.
How to store KYNMOBI
  • Store KYNMOBI at room temperature between 68°F to 77°F (20°C to 25°C).
  • Keep KYNMOBI in the foil pouch until you are ready to take it.
  • Keep KYNMOBI and all medicines out of the reach of children.
How KYNMOBI is packaged
Inside each child-resistant carton is a plastic tray with a pull-out handle that holds the sealed pouches of KYNMOBI sublingual film (see Figure A ). Each KYNMOBI sublingual film comes in a sealed foil pouch (see Figure B ).
Figure A

kyn00 0007 04.jpg
Figure B
kyn00 0007 05.jpg
ATTENTION: Read the Instructions for Use on the other side of this leaflet.

kyn00 0007 03.jpg

INSTRUCTIONS FOR USE
Instructions on How to Use the Child-Resistant Carton
STEP 1 Open Carton
Open carton from the end with the arrow. Push in both tabs to unlock. Hold tabs in. (See Figure C .)
Lift up tray handle. Pull out tray (see Figure D ). 		STEP 2 Remove Pouch
Push finger up through the hole in the bottom of tray. (See Figure E .)
Firmly pull one (1) pouch from the tray (see Figure F ). 		STEP 3 Close Carton
To close, slide tray in until it clicks. (See Figure G .)
This ensures the carton remains child resistant (see Figure H ).
kyn00 0007 06.jpg
kyn00 0007 08.jpg
kyn00 0007 10.jpg
Figure C Figure E Figure G
kyn00 0007 07.jpg
kyn00 0007 09.jpg
kyn00 0007 11.jpg
Figure D Figure F Figure H
Instructions for Taking KYNMOBI
Step 4
  • Your healthcare provider has told you to take KYNMOBI 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg. Complete Steps 5 through 10 to take KYNMOBI.
 Step 5
Drink water. Before taking each KYNMOBI, drink water to moisten your mouth.
This helps the film dissolve more easily (see Figure I ).
 Step 6
Open the KYNMOBI foil pouch.
Hold the wing tabs on the pouch between your thumb and pointer finger of each hand. Make sure to place your fingers directly on the raised dots on each wing tab.
Gently pull the wing tabs apart to open the pouch
(see Figure J ). 		Step 7
Take KYNMOBI out of the pouch.
Hold KYNMOBI between your fingers by the outside edges and remove the entire KYNMOBI from the pouch (see Figure K).
KYNMOBI must be taken whole. Throw away KYNMOBI if it is broken or missing pieces. Use a new KYNMOBI for your dose.

kyn00 0007 12.jpg
Figure I
kyn00 0007 14.jpg
Figure K
kyn00 0007 13.jpg
Figure J

Step 8
Place entire KYNMOBI under your tongue. Place KYNMOBI as far back under your tongue as you can (see Figure L ).
Close your mouth.

 Step 9
Keep KYNMOBI in place until it has completely dissolved (see Figure M ).
  • Do not chew or swallow KYNMOBI.

  • Do not swallow your saliva or talk while KYNMOBI is dissolving because this can affect how well the medicine in KYNMOBI is absorbed.

 Step 10
Open your mouth to check if KYNMOBI has completely dissolved.
It can take about 3 minutes for KYNMOBI to dissolve.
After the film completely dissolves, you may swallow.
kyn00 0007 15.jpg
Figure L
kyn00 0007 16.jpg
Figure M
For assistance with the KYNMOBI child-resistant carton, please ask your care partner for help.
You may also contact your doctor or Sunovion Customer Service at 1-888-394-7377 with questions or for support.
This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured for Sunovion Pharmaceuticals Inc. Marlborough, Massachusetts 01752 USA.
KYNMOBI and

kyn00 0007 30.jpg

are trademarks of Sunovion Pharmaceuticals Inc.
SUNOVION and

kyn00 0007 29.jpg

are registered trademarks of Sumitomo Dainippon Pharma Co. Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co. Ltd.
©2020 Sunovion Pharmaceuticals Inc. All rights reserved.
Issued 5/2020
10414-01

(See reverse side for additional information)

PRINCIPAL DISPLAY PANEL – TRADE POUCH LABEL – 10 mg

NDC 63402-010-01 1 sublingual film

Apomorphine HCl

sublingual film

10 mg

For Sublingual Use Only

Rx only

SUNOVION

kyn00 0007 17.jpg

PRINCIPAL DISPLAY PANEL – TRADE POUCH LABEL – 15 mg

NDC 63402-015-01 1 sublingual film

Apomorphine HCl

sublingual film

15 mg

For Sublingual Use Only

Rx only

SUNOVION

kyn00 0007 18.jpg

PRINCIPAL DISPLAY PANEL – TRADE POUCH LABEL – 20 mg

NDC 63402-020-01 1 sublingual film

Apomorphine HCl

sublingual film

20 mg

For Sublingual Use Only

Rx only

SUNOVION

kyn00 0007 21.jpg

PRINCIPAL DISPLAY PANEL – TRADE POUCH LABEL – 25 mg

NDC 63402-025-01 1 sublingual film

Apomorphine HCl

sublingual film

25 mg

For Sublingual Use Only

Rx only

SUNOVION

kyn00 0007 20.jpg

PRINCIPAL DISPLAY PANEL – TRADE POUCH LABEL – 30 mg

NDC 63402-030-01 1 sublingual film

Apomorphine HCl

sublingual film

30 mg

For Sublingual Use Only

Rx only

SUNOVION

kyn00 0007 19.jpg

PRINCIPAL DISPLAY PANEL – TRADE CARTON – 10 mg

NDC 63402-010-30 30 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

10 mg

For Sublingual Use Only

ATTENTION DISPENSER:

Each time KYNMOBI is dispensed give the patient the Instructions for Use, also provided at www.kynmobi.com/cr-ifu.pdf

Rx only

SUNOVION

kyn00 0007 22.jpg

PRINCIPAL DISPLAY PANEL – TRADE CARTON – 15 mg

NDC 63402-015-30 30 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

15 mg

For Sublingual Use Only

ATTENTION DISPENSER:

Each time KYNMOBI is dispensed give the patient the Instructions for Use, also provided at www.kynmobi.com/cr-ifu.pdf

Rx only

SUNOVION

kyn00 0007 23.jpg

PRINCIPAL DISPLAY PANEL – TRADE CARTON – 20 mg

NDC 63402-020-30 30 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

20 mg

For Sublingual Use Only

ATTENTION DISPENSER:

Each time KYNMOBI is dispensed give the patient the Instructions for Use, also provided at www.kynmobi.com/cr-ifu.pdf

Rx only

SUNOVION

kyn00 0007 24.jpg

PRINCIPAL DISPLAY PANEL – TRADE CARTON – 25 mg

NDC 63402-025-30 30 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

25 mg

For Sublingual Use Only

ATTENTION DISPENSER:

Each time KYNMOBI is dispensed give the patient the Instructions for Use, also provided at www.kynmobi.com/cr-ifu.pdf

Rx only

SUNOVION

kyn00 0007 25.jpg

PRINCIPAL DISPLAY PANEL – TRADE CARTON – 30 mg

NDC 63402-030-30 30 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

30 mg

For Sublingual Use Only

ATTENTION DISPENSER:

Each time KYNMOBI is dispensed give the patient the Instructions for Use, also provided at www.kynmobi.com/cr-ifu.pdf

Rx only

SUNOVION

kyn00 0007 26.jpg

PRINCIPAL DISPLAY PANEL – TRADE OUTER TITRATION CARTON – 10 mg, 15 mg, 20 mg, 25 mg, 30 mg

NDC 63402-088-10 10 pouches each containing 1 sublingual film

KYNMOBI™

(apomorphine HCl) sublingual film

10 mg 15 mg 20 mg 25 mg 30 mg

For Sublingual Use Only

Rx only

READ THE INSTRUCTIONS INSIDE THE TOP PANEL AND READ THE COMPLETE INSTRUCTIONS FOR USE BEFORE TAKING KYNMOBITM

SUNOVION

kyn00 0007 27.jpg

PRINCIPAL DISPLAY PANEL – SAMPLE TITRATION CARTON – 10 mg, 15 mg, 20 mg, 25 mg, 30 mg

NDC 63402-188-10 10 pouches each containing 1 sublingual film

PROFESSIONAL SAMPLE – NOT FOR SALE OR REIMBURSEMENT

KYNMOBI™

(apomorphine HCl) sublingual film

10 mg 15 mg 20 mg 25 mg 30 mg

For Sublingual Use Only

Rx only

READ THE INSTRUCTIONS INSIDE THE TOP PANEL AND READ THE COMPLETE INSTRUCTIONS FOR USE BEFORE TAKING KYNMOBITM

CONTENTS OF THIS KIT:

KYNMOBI 10 mg: 2 pouches, each containing 1 sublingual film

KYNMOBI 15 mg: 2 pouches, each containing 1 sublingual film

KYNMOBI 20 mg: 2 pouches, each containing 1 sublingual film

KYNMOBI 25 mg: 2 pouches, each containing 1 sublingual film

KYNMOBI 30 mg: 2 pouches, each containing 1 sublingual film

SUNOVION

kyn00 0007 28.jpg

also known as
This drug label information is as submitted to the Food and Drug Administration (FDA) and is intended for informational purposes only. If you think you may have a medical emergency, immediately call your doctor or dial 911. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Search Drugs and Medication

Or Browse by Name

At Healthgrades, our Editorial Team works hard to develop complete, objective and meaningful health information to help people choose the right doctor, right hospital and right care. Our writers include physicians, pharmacists, and registered nurses with firsthand clinical experience. All condition, treatment and wellness content is medically reviewed by at least one medical professional ensuring the most accurate information possible. Learn more about our editorial process.

Healthgrades Editorial Process